November 25, 2016 - By Adrian Mccoy
Eli Lilly (NYSE:LLY) was lowered by Atlantic Equities from a “Overweight” rating to a “Neutral” rating in a analysts note shared with investors and clients on Friday, 25 November.
Out of 15 analysts covering Eli Lilly and Company (NYSE:LLY), 14 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. $125 is the highest target while $75 is the lowest. The $97.88 average target is 41.61% above today’s ($69.12) stock price. Eli Lilly and Company has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock of Eli Lilly and Co (NYSE:LLY) has “Outperform” rating given on Monday, August 24 by Cowen & Co. The rating was maintained by Cowen & Co on Saturday, August 22 with “Outperform”. Deutsche Bank upgraded Eli Lilly and Co (NYSE:LLY) rating on Monday, December 7. Deutsche Bank has “Buy” rating and $99 price target. The firm has “Buy” rating given on Tuesday, September 27 by Goldman Sachs. On Tuesday, August 2 the stock rating was maintained by Argus Research with “Buy”. The rating was maintained by Jefferies on Friday, September 18 with “Buy”. The stock has “Buy” rating given by Jefferies on Tuesday, March 15. On Thursday, July 14 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Friday, September 18 by Bank of America. The company was initiated on Friday, December 18 by Atlantic Securities.
The stock increased 1.65% or $1.12 during the last trading session, hitting $69.12. About 8.58 million shares traded hands or 44.44% up from the average. Eli Lilly and Co (NYSE:LLY) has declined 12.63% since April 22, 2016 and is downtrending. It has underperformed by 18.04% the S&P500.
Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on January, 31 before the open. They expect $0.99 earnings per share, up 26.92% or $0.21 from last year’s $0.78 per share. LLY’s profit will be $977.97M for 17.45 P/E if the $0.99 EPS becomes a reality. After $0.88 actual earnings per share reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 12.50% EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.08 in Q2 2016. Its up 0.01, from 1.07 in 2016Q1. The ratio improved, as 54 funds sold all Eli Lilly and Co shares owned while 365 reduced positions. 88 funds bought stakes while 362 increased positions. They now own 814.98 million shares or 2.31% less from 834.25 million shares in 2016Q1.
Commerzbank Aktiengesellschaft Fi accumulated 0.05% or 88,954 shares. Aull Monroe Invest Mgmt accumulated 19,173 shares or 0.87% of the stock. Segall Bryant & Hamill Lc has invested 0.02% of its portfolio in Eli Lilly and Co (NYSE:LLY). Moreover, Mcgowan Grp Asset Mngmt has 0.3% invested in Eli Lilly and Co (NYSE:LLY) for 21,348 shares. Riggs Asset Managment Company accumulated 0% or 31 shares. Ipswich Inv Mgmt Com has 8,280 shares for 0.32% of their US portfolio. Cullen Mngmt Llc owns 699,555 shares or 1.94% of their US portfolio. Natl Bank Of Ny Mellon, a New York-based fund reported 14.18 million shares. Montag A & Assocs owns 50,760 shares or 0.53% of their US portfolio. Kcg Inc has 0.04% invested in the company for 25,207 shares. Rothschild Inv Corporation Il has invested 0.26% of its portfolio in Eli Lilly and Co (NYSE:LLY). Tt holds 26,379 shares or 0.7% of its portfolio. Spears Abacus Advsrs Ltd Liability Co holds 0.06% of its portfolio in Eli Lilly and Co (NYSE:LLY) for 6,350 shares. Moreover, Advisory Service Limited Liability Co has 0.14% invested in Eli Lilly and Co (NYSE:LLY) for 7,912 shares. Cypress Asset Inc Tx holds 1.43% or 91,112 shares in its portfolio.
Insider Transactions: Since May 31, 2016, the stock had 1 buying transaction, and 10 selling transactions for $120.57 million net activity. On Wednesday, June 29 the insider LILLY ENDOWMENT INC sold $17.13 million. 1,213 Eli Lilly and Co (NYSE:LLY) shares with value of $100,873 were sold by Zakrowski Donald A. Barnes Melissa S sold $73,180 worth of Eli Lilly and Co (NYSE:LLY) on Friday, June 10. On Tuesday, October 4 Crowe Maria A sold $182,927 worth of the stock or 2,248 shares. Another trade for 2,560 shares valued at $205,875 was bought by TAI JACKSON P.
Eli Lilly and Company is engaged in drug manufacturing business. The company has a market cap of $68.28 billion. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. It has a 30.02 P/E ratio. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.”
Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.
More notable recent Eli Lilly and Co (NYSE:LLY) news were published by: Marketwatch.com which released: “Eli Lilly shares slide premarket after company says Alzheimer’s drug trial failed” on November 23, 2016, also Marketwatch.com with their article: “Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails” published on November 25, 2016, Fool.com published: “Better Buy: Eli Lilly and Co vs. Pfizer” on October 26, 2016. More interesting news about Eli Lilly and Co (NYSE:LLY) were released by: Forbes.com and their article: “January 2017 Options Now Available For Eli Lilly (LLY)” published on November 23, 2016 as well as Schaeffersresearch.com‘s news article titled: “Buzz Stocks: Juno Therapeutics Inc, Eli Lilly and Co, and Biogen Inc” with publication date: November 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy